1. From the Department of Health Policy and Management and
2. the Center for Clinical Trials, Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland;
3. the Department of Ophthalmology/Scheie Eye Institute, the 4Center for Clinical Epidemiology and Biostatistics, and the Departments of 5Biostatistics and Epidemiology and 6Oncology, The University of Pennsylvania, Philadelphia, Pennsylvania;
4. the Department of Ophthalmology/Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltimore, Maryland;
5. the Department of Ophthalmology/Jules Stein Eye Institute, The David Geffen School of Medicine at UCLA, Los Angeles, California;
6. the Department of Ophthalmology, New York Eye and Ear Institute, New York, New York;
7. the Department of Ophthalmology/Doheny Eye Institute, USC School of Medicine, Los Angeles, California;
8. the National Eye Institute, National Institutes of Health, Bethesda, Maryland;
9. the Center for Clinical Trials, Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; the Departments of 12Oncology and 13Biostatistics, The Johns Hopkins University, Baltimore, Maryland; and
10. the Center for Clinical Trials, Department of Epidemiology, The Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland; the 7Department of Ophthalmology/Wilmer Eye Institute, The Johns Hopkins University School of Medicine, Baltim
11. Texas Retina Associates, Dallas, Texas.